Skip to main content
Erschienen in: Acta Neurologica Belgica 2/2019

13.03.2019 | Review article

The current and emerging therapeutic approaches in drug-resistant epilepsy management

verfasst von: Amir Mehdizadeh, Mohammad Barzegar, Sohrab Negargar, Azita Yahyavi, Sina Raeisi

Erschienen in: Acta Neurologica Belgica | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Epilepsy is a neurologic disorder consisting of recurrent spontaneous seizures. Antiepileptic drugs administration is the most commonly used therapeutic strategy in the management of epilepsy. However, 20–30% of epilepsy patients have seizure episodes that are not controlled by these medicines (drug-resistant epilepsy). The management of drug-resistant epilepsy, especially in the children, is challenging and can cause economic and social problems, and lower the patients’ quality of life, cognition, and mood. Several therapeutic approaches for drug-resistant epilepsy are available including surgical methods, neurostimulation treatments, and diet therapies which lead to diminishing the epileptic seizures. An increasing number of novel and potential therapeutic approaches such as gene therapy, gene editing, cell therapy, exosome therapy, and molecular network targeting have also been explored. The present study is aimed to review these current and emerging therapeutic approaches for drug-resistant epilepsy.
Literatur
1.
Zurück zum Zitat Hodges SL, Lugo JN (2018) Wnt/β-catenin signaling as a potential target for novel epilepsy therapies. Epilepsy Res 146:9–16PubMedCrossRef Hodges SL, Lugo JN (2018) Wnt/β-catenin signaling as a potential target for novel epilepsy therapies. Epilepsy Res 146:9–16PubMedCrossRef
2.
Zurück zum Zitat Nunes ML, Appel CC, da Costa JC (2003) Apparent life-threatening episodes as the first manifestation of epilepsy. Clin Pediatr 42(1):19–22CrossRef Nunes ML, Appel CC, da Costa JC (2003) Apparent life-threatening episodes as the first manifestation of epilepsy. Clin Pediatr 42(1):19–22CrossRef
3.
Zurück zum Zitat Barzegar M, Mahdavi M, Behbehani AG, Tabrizi A (2015) Refractory convulsive status epilepticus in children: etiology, associated risk factors and outcome. Iran J Child Neurol 9(4):24PubMedPubMedCentral Barzegar M, Mahdavi M, Behbehani AG, Tabrizi A (2015) Refractory convulsive status epilepticus in children: etiology, associated risk factors and outcome. Iran J Child Neurol 9(4):24PubMedPubMedCentral
4.
Zurück zum Zitat Papandreou D, Pavlou E, Kalimeri E, Mavromichalis I (2006) The ketogenic diet in children with epilepsy. Br J Nutr 95(1):5–13PubMedCrossRef Papandreou D, Pavlou E, Kalimeri E, Mavromichalis I (2006) The ketogenic diet in children with epilepsy. Br J Nutr 95(1):5–13PubMedCrossRef
5.
Zurück zum Zitat Cunnane S, Musa K, Ryan M, Whiting S, Fraser D (2002) Potential role of polyunsaturates in seizure protection achieved with the ketogenic diet. Prostaglandins Leukot Essent Fatty Acids 67(2–3):131–135PubMedCrossRef Cunnane S, Musa K, Ryan M, Whiting S, Fraser D (2002) Potential role of polyunsaturates in seizure protection achieved with the ketogenic diet. Prostaglandins Leukot Essent Fatty Acids 67(2–3):131–135PubMedCrossRef
6.
Zurück zum Zitat Giussani G, Cricelli C, Mazzoleni F, Cricelli I, Pasqua A, Pecchioli S, Lapi F, Beghi E (2014) Prevalence and incidence of epilepsy in Italy based on a nationwide database. Neuroepidemiology 43(3–4):228–232PubMedCrossRef Giussani G, Cricelli C, Mazzoleni F, Cricelli I, Pasqua A, Pecchioli S, Lapi F, Beghi E (2014) Prevalence and incidence of epilepsy in Italy based on a nationwide database. Neuroepidemiology 43(3–4):228–232PubMedCrossRef
7.
Zurück zum Zitat Lauritzen F, Eid T, Bergersen LH (2015) Monocarboxylate transporters in temporal lobe epilepsy: roles of lactate and ketogenic diet. Brain Struct Funct 220(1):1–12PubMedCrossRef Lauritzen F, Eid T, Bergersen LH (2015) Monocarboxylate transporters in temporal lobe epilepsy: roles of lactate and ketogenic diet. Brain Struct Funct 220(1):1–12PubMedCrossRef
8.
Zurück zum Zitat Kobau R, Zahran H, Thurman DJ, Zack MM, Henry TR, Schachter SC, Price PH (2008) Epilepsy surveillance among adults–19 states, behavioral risk factor surveillance system, 2005. MMWR Surveill Summ 57(6):1–20PubMed Kobau R, Zahran H, Thurman DJ, Zack MM, Henry TR, Schachter SC, Price PH (2008) Epilepsy surveillance among adults–19 states, behavioral risk factor surveillance system, 2005. MMWR Surveill Summ 57(6):1–20PubMed
9.
Zurück zum Zitat Mohanraj R, Brodie M (2006) Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur J Neurol 13(3):277–282PubMedCrossRef Mohanraj R, Brodie M (2006) Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur J Neurol 13(3):277–282PubMedCrossRef
10.
Zurück zum Zitat Campos G, Fortuna A, Falcão A, Alves G (2018) In vitro and in vivo experimental models employed in the discovery and development of antiepileptic drugs for pharmacoresistant epilepsy. Epilepsy Res 146:63–86PubMedCrossRef Campos G, Fortuna A, Falcão A, Alves G (2018) In vitro and in vivo experimental models employed in the discovery and development of antiepileptic drugs for pharmacoresistant epilepsy. Epilepsy Res 146:63–86PubMedCrossRef
11.
Zurück zum Zitat Liu X, Han Q (2015) Risk factors on health-related quality of life in children with epilepsy. Clin Pediatr 54(14):1334–1338CrossRef Liu X, Han Q (2015) Risk factors on health-related quality of life in children with epilepsy. Clin Pediatr 54(14):1334–1338CrossRef
12.
Zurück zum Zitat Valizadeh L, Barzegar M, Akbarbegloo M, Zamanzadeh V, Rahiminia E, Ferguson C (2013) The relationship between psychosocial care and attitudes toward illness in adolescents with epilepsy. Epilepsy Behav 27(1):267–271PubMedCrossRef Valizadeh L, Barzegar M, Akbarbegloo M, Zamanzadeh V, Rahiminia E, Ferguson C (2013) The relationship between psychosocial care and attitudes toward illness in adolescents with epilepsy. Epilepsy Behav 27(1):267–271PubMedCrossRef
13.
Zurück zum Zitat Cottrell L, Khan A (2005) Impact of childhood epilepsy on maternal sleep and socioemotional functioning. Clin Pediatr 44(7):613–616CrossRef Cottrell L, Khan A (2005) Impact of childhood epilepsy on maternal sleep and socioemotional functioning. Clin Pediatr 44(7):613–616CrossRef
14.
Zurück zum Zitat Boison D (2007) Cell and gene therapies for refractory epilepsy. Curr Neuropharmacol 5(2):115–125PubMedCrossRef Boison D (2007) Cell and gene therapies for refractory epilepsy. Curr Neuropharmacol 5(2):115–125PubMedCrossRef
15.
17.
18.
Zurück zum Zitat Prideaux L, Barton S, Maixner W, Harvey AS (2018) Potential delays in referral and assessment for epilepsy surgery in children with drug-resistant, early-onset epilepsy. Epilepsy Res 143:20–26PubMedCrossRef Prideaux L, Barton S, Maixner W, Harvey AS (2018) Potential delays in referral and assessment for epilepsy surgery in children with drug-resistant, early-onset epilepsy. Epilepsy Res 143:20–26PubMedCrossRef
19.
Zurück zum Zitat Lukmanji S, Altura KC, Rydenhag B, Malmgren K, Wiebe S, Jetté N (2018) Accuracy of an online tool to assess appropriateness for an epilepsy surgery evaluation–A population-based Swedish study. Epilepsy Res 145:140–144PubMedCrossRef Lukmanji S, Altura KC, Rydenhag B, Malmgren K, Wiebe S, Jetté N (2018) Accuracy of an online tool to assess appropriateness for an epilepsy surgery evaluation–A population-based Swedish study. Epilepsy Res 145:140–144PubMedCrossRef
20.
Zurück zum Zitat Ventureyra EC, Higgins MJ (1993) Complications of epilepsy surgery in children and adolescents. Pediatr Neurosurg 19(1):40–56PubMedCrossRef Ventureyra EC, Higgins MJ (1993) Complications of epilepsy surgery in children and adolescents. Pediatr Neurosurg 19(1):40–56PubMedCrossRef
21.
Zurück zum Zitat Olson DM (2001) Evaluation of children for epilepsy surgery. Pediatric Neurosurg 34(3):159–165CrossRef Olson DM (2001) Evaluation of children for epilepsy surgery. Pediatric Neurosurg 34(3):159–165CrossRef
22.
Zurück zum Zitat Nordli DR, Kelley KR (2001) Selection and evaluation of children for epilepsy surgery. Pediatric Neurosurg 34(1):1–12CrossRef Nordli DR, Kelley KR (2001) Selection and evaluation of children for epilepsy surgery. Pediatric Neurosurg 34(1):1–12CrossRef
23.
Zurück zum Zitat Pati S, Alexopoulos AV (2010) Pharmacoresistant epilepsy: from pathogenesis to current and emerging therapies. Cleve Clin J Med 77(7):457–567PubMedCrossRef Pati S, Alexopoulos AV (2010) Pharmacoresistant epilepsy: from pathogenesis to current and emerging therapies. Cleve Clin J Med 77(7):457–567PubMedCrossRef
24.
Zurück zum Zitat Rajesh P, Bejoy T, VS CP, Kesavadas C, Ashalatha R, Aley A (2018) Hippocampal activations in mesial temporal lobe epilepsy due to hippocampal sclerosis-an observational study on intramural encoding-delayed recall paradigms using task-based memory fMRI. Epilepsy Res 145:31–39PubMedCrossRef Rajesh P, Bejoy T, VS CP, Kesavadas C, Ashalatha R, Aley A (2018) Hippocampal activations in mesial temporal lobe epilepsy due to hippocampal sclerosis-an observational study on intramural encoding-delayed recall paradigms using task-based memory fMRI. Epilepsy Res 145:31–39PubMedCrossRef
25.
Zurück zum Zitat Schusse CM, Smith K, Drees C (2018) Outcomes after hemispherectomy in adult patients with intractable epilepsy: institutional experience and systematic review of the literature. J Neurosurg 128(3):853–861PubMedCrossRef Schusse CM, Smith K, Drees C (2018) Outcomes after hemispherectomy in adult patients with intractable epilepsy: institutional experience and systematic review of the literature. J Neurosurg 128(3):853–861PubMedCrossRef
26.
Zurück zum Zitat Griessenauer CJ, Salam S, Hendrix P, Patel DM, Tubbs RS, Blount JP, Winkler PA (2015) Hemispherectomy for treatment of refractory epilepsy in the pediatric age group: a systematic review. J Neurosurg Pediatr 15(1):34–44PubMedCrossRef Griessenauer CJ, Salam S, Hendrix P, Patel DM, Tubbs RS, Blount JP, Winkler PA (2015) Hemispherectomy for treatment of refractory epilepsy in the pediatric age group: a systematic review. J Neurosurg Pediatr 15(1):34–44PubMedCrossRef
27.
Zurück zum Zitat Beleza P (2009) Refractory epilepsy: a clinically oriented review. Eur Neuro 62(2):65–71CrossRef Beleza P (2009) Refractory epilepsy: a clinically oriented review. Eur Neuro 62(2):65–71CrossRef
28.
Zurück zum Zitat Panebianco M, Rigby A, Weston J, Marson AG (2015) Vagus nerve stimulation for partial seizures. Cochrane Database Syst Rev 3(4):CD002896 Panebianco M, Rigby A, Weston J, Marson AG (2015) Vagus nerve stimulation for partial seizures. Cochrane Database Syst Rev 3(4):CD002896
29.
Zurück zum Zitat Ben-Menachem E, Revesz D, Simon B, Silberstein S (2015) Surgically implanted and non-invasive vagus nerve stimulation: a review of efficacy, safety and tolerability. Eur J Neurol 22(9):1260–1268PubMedPubMedCentralCrossRef Ben-Menachem E, Revesz D, Simon B, Silberstein S (2015) Surgically implanted and non-invasive vagus nerve stimulation: a review of efficacy, safety and tolerability. Eur J Neurol 22(9):1260–1268PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Finetti C (2015) P90. Transcutaneous vagus nerve stimulation (t-VNS) in a child with dravet syndrome–a case report. Clin Neurophysiol 126(8):e147CrossRef Finetti C (2015) P90. Transcutaneous vagus nerve stimulation (t-VNS) in a child with dravet syndrome–a case report. Clin Neurophysiol 126(8):e147CrossRef
31.
Zurück zum Zitat Amar AP, Levy ML, McComb JG, Apuzzo ML (2001) Vagus nerve stimulation for control of intractable seizures in childhood. Pediatr Neurosurg 34(4):218–223PubMedCrossRef Amar AP, Levy ML, McComb JG, Apuzzo ML (2001) Vagus nerve stimulation for control of intractable seizures in childhood. Pediatr Neurosurg 34(4):218–223PubMedCrossRef
32.
Zurück zum Zitat Schulze-Bonhage A (2017) Brain stimulation as a neuromodulatory epilepsy therapy. Seizure 44:169–175PubMedCrossRef Schulze-Bonhage A (2017) Brain stimulation as a neuromodulatory epilepsy therapy. Seizure 44:169–175PubMedCrossRef
33.
Zurück zum Zitat Wilder R (1921) The effects of ketonemia on the course of epilepsy. In Mayo Clin Proc 2:307–308 Wilder R (1921) The effects of ketonemia on the course of epilepsy. In Mayo Clin Proc 2:307–308
35.
Zurück zum Zitat Gonzalez FL, Osorio XR, Rein AG-N, Martinez MC, Fernandez JS, Haba VV, Pedraza AD, Cerdá JM (2015) Drug-resistant epilepsy: definition and treatment alternatives. Neurologia 30(7):439–446CrossRef Gonzalez FL, Osorio XR, Rein AG-N, Martinez MC, Fernandez JS, Haba VV, Pedraza AD, Cerdá JM (2015) Drug-resistant epilepsy: definition and treatment alternatives. Neurologia 30(7):439–446CrossRef
36.
Zurück zum Zitat Rezaei S, Kavoosi M, Badv RS, Mohammadi M, Zamani GR, Ashrafi MR, Yekaninejad MS, Mahmoudi M, Crossen K, Tehranian A (2017) The influence of ketogenic diet on liver function in children and adolescents with intractable epilepsy. J Compr Pediatr 8(3):e12609 Rezaei S, Kavoosi M, Badv RS, Mohammadi M, Zamani GR, Ashrafi MR, Yekaninejad MS, Mahmoudi M, Crossen K, Tehranian A (2017) The influence of ketogenic diet on liver function in children and adolescents with intractable epilepsy. J Compr Pediatr 8(3):e12609
37.
Zurück zum Zitat Kossoff EH, Shields WD (2014) Nonpharmacologic care for patients with Lennox-Gastaut syndrome: Ketogenic diets and vagus nerve stimulation. Epilepsia 55(s4):29–33PubMedCrossRef Kossoff EH, Shields WD (2014) Nonpharmacologic care for patients with Lennox-Gastaut syndrome: Ketogenic diets and vagus nerve stimulation. Epilepsia 55(s4):29–33PubMedCrossRef
38.
Zurück zum Zitat Spulber G, Spulber S, Hagenäs L, Åmark P, Dahlin M (2009) Growth dependence on insulin-like growth factor-1 during the ketogenic diet. Epilepsia 50(2):297–303PubMedCrossRef Spulber G, Spulber S, Hagenäs L, Åmark P, Dahlin M (2009) Growth dependence on insulin-like growth factor-1 during the ketogenic diet. Epilepsia 50(2):297–303PubMedCrossRef
40.
Zurück zum Zitat Miranda MJ, Turner Z, Magrath G (2012) Alternative diets to the classical ketogenic diet—Can we be more liberal? Epilepsy Res 100(3):278–285PubMedCrossRef Miranda MJ, Turner Z, Magrath G (2012) Alternative diets to the classical ketogenic diet—Can we be more liberal? Epilepsy Res 100(3):278–285PubMedCrossRef
41.
Zurück zum Zitat Katyal NG, Koehler AN, McGhee B, Foley CM, Crumrine PK (2000) The ketogenic diet in refractory epilepsy: the experience of Children’s Hospital of Pittsburgh. Clin Pediatr 39(3):153–159CrossRef Katyal NG, Koehler AN, McGhee B, Foley CM, Crumrine PK (2000) The ketogenic diet in refractory epilepsy: the experience of Children’s Hospital of Pittsburgh. Clin Pediatr 39(3):153–159CrossRef
42.
Zurück zum Zitat Milder J, Patel M (2012) Modulation of oxidative stress and mitochondrial function by the ketogenic diet. Epilepsy Res 100(3):295–303PubMedCrossRef Milder J, Patel M (2012) Modulation of oxidative stress and mitochondrial function by the ketogenic diet. Epilepsy Res 100(3):295–303PubMedCrossRef
43.
Zurück zum Zitat Sudha K, Rao AV, Rao A (2001) Oxidative stress and antioxidants in epilepsy. Clin Chim Acta 303(1–2):19–24PubMedCrossRef Sudha K, Rao AV, Rao A (2001) Oxidative stress and antioxidants in epilepsy. Clin Chim Acta 303(1–2):19–24PubMedCrossRef
44.
Zurück zum Zitat Shin E-J, Jeong JH, Chung YH, Kim W-K, Ko K-H, Bach J-H, Hong J-S, Yoneda Y, Kim H-C (2011) Role of oxidative stress in epileptic seizures. Neurochem Int 59(2):122–137PubMedPubMedCentralCrossRef Shin E-J, Jeong JH, Chung YH, Kim W-K, Ko K-H, Bach J-H, Hong J-S, Yoneda Y, Kim H-C (2011) Role of oxidative stress in epileptic seizures. Neurochem Int 59(2):122–137PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Rao G, Mashkouri S, Aum D, Marcet P, Borlongan CV (2017) Contemplating stem cell therapy for epilepsy-induced neuropsychiatric symptoms. Neuropsychiatr Dis Treat 13:585–596PubMedPubMedCentralCrossRef Rao G, Mashkouri S, Aum D, Marcet P, Borlongan CV (2017) Contemplating stem cell therapy for epilepsy-induced neuropsychiatric symptoms. Neuropsychiatr Dis Treat 13:585–596PubMedPubMedCentralCrossRef
46.
Zurück zum Zitat Simonato M, Bennett J, Boulis NM, Castro MG, Fink DJ, Goins WF, Gray SJ, Lowenstein PR, Vandenberghe LH, Wilson TJ (2013) Progress in gene therapy for neurological disorders. Nat Rev Neuro 9(5):277–291CrossRef Simonato M, Bennett J, Boulis NM, Castro MG, Fink DJ, Goins WF, Gray SJ, Lowenstein PR, Vandenberghe LH, Wilson TJ (2013) Progress in gene therapy for neurological disorders. Nat Rev Neuro 9(5):277–291CrossRef
48.
49.
Zurück zum Zitat Noè F, Pool A-H, Nissinen J, Gobbi M, Bland R, Rizzi M, Balducci C, Ferraguti F, Sperk G, During MJ (2008) Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain 131(6):1506–1515PubMedCrossRef Noè F, Pool A-H, Nissinen J, Gobbi M, Bland R, Rizzi M, Balducci C, Ferraguti F, Sperk G, During MJ (2008) Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain 131(6):1506–1515PubMedCrossRef
50.
Zurück zum Zitat Raol YH, Lund IV, Bandyopadhyay S, Zhang G, Roberts DS, Wolfe JH, Russek SJ, Brooks-Kayal AR (2006) Enhancing GABAA receptor α1 subunit levels in hippocampal dentate gyrus inhibits epilepsy development in an animal model of temporal lobe epilepsy. J Neurosci 26(44):11342–11346PubMedPubMedCentralCrossRef Raol YH, Lund IV, Bandyopadhyay S, Zhang G, Roberts DS, Wolfe JH, Russek SJ, Brooks-Kayal AR (2006) Enhancing GABAA receptor α1 subunit levels in hippocampal dentate gyrus inhibits epilepsy development in an animal model of temporal lobe epilepsy. J Neurosci 26(44):11342–11346PubMedPubMedCentralCrossRef
51.
Zurück zum Zitat Haberman RP, Samulski RJ, McCown TJ (2003) Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat Med 9(8):1076–1080PubMedCrossRef Haberman RP, Samulski RJ, McCown TJ (2003) Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat Med 9(8):1076–1080PubMedCrossRef
52.
Zurück zum Zitat Richichi C, Lin E-JD, Stefanin D, Colella D, Ravizza T, Grignaschi G, Veglianese P, Sperk G, During MJ, Vezzani A (2004) Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. J Neurosci 24(12):3051–3059PubMedPubMedCentralCrossRef Richichi C, Lin E-JD, Stefanin D, Colella D, Ravizza T, Grignaschi G, Veglianese P, Sperk G, During MJ, Vezzani A (2004) Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. J Neurosci 24(12):3051–3059PubMedPubMedCentralCrossRef
53.
Zurück zum Zitat Kanter-Schlifke I, Georgievska B, Kirik D, Kokaia M (2007) Seizure suppression by GDNF gene therapy in animal models of epilepsy. Mol Ther 15(6):1106–1113PubMedCrossRef Kanter-Schlifke I, Georgievska B, Kirik D, Kokaia M (2007) Seizure suppression by GDNF gene therapy in animal models of epilepsy. Mol Ther 15(6):1106–1113PubMedCrossRef
54.
Zurück zum Zitat Paradiso B, Zucchini S, Su T, Bovolenta R, Berto E, Marconi P, Marzola A, Mora GN, Fabene PF, Simonato M (2011) Localized overexpression of FGF-2 and BDNF in hippocampus reduces mossy fiber sprouting and spontaneous seizures up to 4 weeks after pilocarpine-induced status epilepticus. Epilepsia 52(3):572–578PubMedCrossRef Paradiso B, Zucchini S, Su T, Bovolenta R, Berto E, Marconi P, Marzola A, Mora GN, Fabene PF, Simonato M (2011) Localized overexpression of FGF-2 and BDNF in hippocampus reduces mossy fiber sprouting and spontaneous seizures up to 4 weeks after pilocarpine-induced status epilepticus. Epilepsia 52(3):572–578PubMedCrossRef
55.
Zurück zum Zitat Paradiso B, Marconi P, Zucchini S, Berto E, Binaschi A, Bozac A, Buzzi A, Mazzuferi M, Magri E, Mora GN (2009) Localized delivery of fibroblast growth factor–2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model. Proc Natl Acad Sci USA 106(17):7191–7196PubMedCrossRefPubMedCentral Paradiso B, Marconi P, Zucchini S, Berto E, Binaschi A, Bozac A, Buzzi A, Mazzuferi M, Magri E, Mora GN (2009) Localized delivery of fibroblast growth factor–2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model. Proc Natl Acad Sci USA 106(17):7191–7196PubMedCrossRefPubMedCentral
56.
Zurück zum Zitat Mollanoori H, Teimourian S (2018) Therapeutic applications of CRISPR/Cas9 system in gene therapy. Biotechnol Lett 40:907–914PubMedCrossRef Mollanoori H, Teimourian S (2018) Therapeutic applications of CRISPR/Cas9 system in gene therapy. Biotechnol Lett 40:907–914PubMedCrossRef
57.
Zurück zum Zitat Savić N, Schwank G (2016) Advances in therapeutic CRISPR/Cas9 genome editing. Transl Res 168:15–21PubMedCrossRef Savić N, Schwank G (2016) Advances in therapeutic CRISPR/Cas9 genome editing. Transl Res 168:15–21PubMedCrossRef
58.
Zurück zum Zitat Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E (2012) A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. Science 337(6096):816–821PubMedPubMedCentralCrossRef Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E (2012) A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. Science 337(6096):816–821PubMedPubMedCentralCrossRef
59.
Zurück zum Zitat Wykes R, Lignani G (2018) Gene therapy and editing: Novel potential treatments for neuronal channelopathies. Neuropharmacology 132:108–117PubMedCrossRef Wykes R, Lignani G (2018) Gene therapy and editing: Novel potential treatments for neuronal channelopathies. Neuropharmacology 132:108–117PubMedCrossRef
60.
61.
Zurück zum Zitat Swiech L, Heidenreich M, Banerjee A, Habib N, Li Y, Trombetta J, Sur M, Zhang F (2015) In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol 33(1):102–106PubMedCrossRef Swiech L, Heidenreich M, Banerjee A, Habib N, Li Y, Trombetta J, Sur M, Zhang F (2015) In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol 33(1):102–106PubMedCrossRef
62.
63.
Zurück zum Zitat Rossi F, Cattaneo E (2002) Neural stem cell therapy for neurological diseases: dreams and reality. Nat Rev Neurosci 3(5):401PubMedCrossRef Rossi F, Cattaneo E (2002) Neural stem cell therapy for neurological diseases: dreams and reality. Nat Rev Neurosci 3(5):401PubMedCrossRef
64.
Zurück zum Zitat Luarte A, Bátiz LF, Wyneken U, Lafourcade C (2016) Potential therapies by stem cell-derived exosomes in CNS diseases: focusing on the neurogenic niche. Stem Cells Int 2016:5736059PubMedPubMedCentralCrossRef Luarte A, Bátiz LF, Wyneken U, Lafourcade C (2016) Potential therapies by stem cell-derived exosomes in CNS diseases: focusing on the neurogenic niche. Stem Cells Int 2016:5736059PubMedPubMedCentralCrossRef
66.
Zurück zum Zitat Kalani A, Tyagi A, Tyagi N (2014) Exosomes: mediators of neurodegeneration, neuroprotection and therapeutics. Mol Neurobiol 49(1):590–600PubMedCrossRef Kalani A, Tyagi A, Tyagi N (2014) Exosomes: mediators of neurodegeneration, neuroprotection and therapeutics. Mol Neurobiol 49(1):590–600PubMedCrossRef
67.
Zurück zum Zitat van Niel G, D’Angelo G, Raposo G (2018) Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol 19(4):213–228PubMedCrossRef van Niel G, D’Angelo G, Raposo G (2018) Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol 19(4):213–228PubMedCrossRef
68.
Zurück zum Zitat Tiwari D, Peariso K, Gross C (2018) MicroRNA-induced silencing in epilepsy: opportunities and challenges for clinical application. Dev Dyn 247(1):94–110PubMedCrossRef Tiwari D, Peariso K, Gross C (2018) MicroRNA-induced silencing in epilepsy: opportunities and challenges for clinical application. Dev Dyn 247(1):94–110PubMedCrossRef
69.
Zurück zum Zitat Henshall DC, Hamer HM, Pasterkamp RJ, Goldstein DB, Kjems J, Prehn JH, Schorge S, Lamottke K, Rosenow F (2016) MicroRNAs in epilepsy: pathophysiology and clinical utility. Lancet Neurol 15(13):1368–1376PubMedCrossRef Henshall DC, Hamer HM, Pasterkamp RJ, Goldstein DB, Kjems J, Prehn JH, Schorge S, Lamottke K, Rosenow F (2016) MicroRNAs in epilepsy: pathophysiology and clinical utility. Lancet Neurol 15(13):1368–1376PubMedCrossRef
71.
Zurück zum Zitat Zeng L-H, Rensing NR, Wong M (2009) The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci 29(21):6964–6972PubMedPubMedCentralCrossRef Zeng L-H, Rensing NR, Wong M (2009) The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci 29(21):6964–6972PubMedPubMedCentralCrossRef
72.
Zurück zum Zitat Xiao Z, Peng J, Gan N, Arafat A, Yin F (2016) Interleukin-1β plays a pivotal role via the PI3K/Akt/mTOR signaling pathway in the chronicity of mesial temporal lobe epilepsy. Neuroimmunomodulation 23(5–6):332–344PubMedCrossRef Xiao Z, Peng J, Gan N, Arafat A, Yin F (2016) Interleukin-1β plays a pivotal role via the PI3K/Akt/mTOR signaling pathway in the chronicity of mesial temporal lobe epilepsy. Neuroimmunomodulation 23(5–6):332–344PubMedCrossRef
73.
Zurück zum Zitat Krueger DA, Wilfong AA, Holland-Bouley K, Anderson AE, Tudor C, Mays M, Lopez CM, Kim MO, Franz DN (2013) Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 74(5):679–687PubMedCrossRef Krueger DA, Wilfong AA, Holland-Bouley K, Anderson AE, Tudor C, Mays M, Lopez CM, Kim MO, Franz DN (2013) Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 74(5):679–687PubMedCrossRef
74.
Zurück zum Zitat Qu Z, Su F, Qi X, Sun J, Wang H, Qiao Z, Zhao H, Zhu Y (2017) Wnt/β-catenin signalling pathway mediated aberrant hippocampal neurogenesis in kainic acid-induced epilepsy. Cell Biochem Funct 35(7):472–476PubMedCrossRef Qu Z, Su F, Qi X, Sun J, Wang H, Qiao Z, Zhao H, Zhu Y (2017) Wnt/β-catenin signalling pathway mediated aberrant hippocampal neurogenesis in kainic acid-induced epilepsy. Cell Biochem Funct 35(7):472–476PubMedCrossRef
Metadaten
Titel
The current and emerging therapeutic approaches in drug-resistant epilepsy management
verfasst von
Amir Mehdizadeh
Mohammad Barzegar
Sohrab Negargar
Azita Yahyavi
Sina Raeisi
Publikationsdatum
13.03.2019
Verlag
Springer International Publishing
Erschienen in
Acta Neurologica Belgica / Ausgabe 2/2019
Print ISSN: 0300-9009
Elektronische ISSN: 2240-2993
DOI
https://doi.org/10.1007/s13760-019-01120-8

Weitere Artikel der Ausgabe 2/2019

Acta Neurologica Belgica 2/2019 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.